On January 8, 2024, Kazia Therapeutics Limited received notice from Karen Krumeich of her intention to resign as the Company?s Chief Financial Officer, effective immediately. Ms. Krumeich?s resignation is not the result of any disagreement between Ms. Krumeich and the Company, its management or board of directors, or related to the Company?s operations, policies or practices. Ms. Krumeich will remain with the Company in an advisory role for a period of time to be mutually agreed between her and the Company to support the transition.